Roth Capital Initiates Dianthus Therapeutics Coverage With Buy Rating
Roth Capital initiated coverage of Dianthus Therapeutics with a Buy rating.
Related stories
TriNet Q3 2026 Worksite Employees Decrease 11% to About 295,000
M impact | EQUITY | Oct 29, 2026, 11:25 AM UTC
Heidelberger Druck Reports Lower Fiscal H1 Sales
M impact | EQUITY | Oct 29, 2026, 11:25 AM UTC
Shell Raises Quarterly Buyback to $5 Billion From $3 Billion
Shell increased its buyback to $5 billion from the $3 billion announced last quarter, following a strong third-quarter performance.
M impact | EQUITY | Oct 29, 2026, 11:25 AM UTC
Crocs shares rise 20.3% premarket after Q3 beat and FY guidance raise
Crocs shares rose 20.3% premarket after Q3 results beat and the company raised its FY guidance.
M impact | EQUITY | Oct 29, 2026, 11:25 AM UTC
Bunge Tops Quarterly Profit Estimates on Strong Crushing Margins
M impact | EQUITY | Oct 29, 2026, 11:25 AM UTC
Sirius XM Reports Q3 Revenue of $2.15 Billion
M impact | EQUITY | Oct 29, 2026, 11:25 AM UTC